AliBukhariMD

Oncology • Annapolis, MD

Hematologic Oncology, Thoracic Cancer

Physician

Join to view full profile

Dr. Bukhari is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Bukhari's full profile

Already have an account?

Office
810 Bestgate Road
Suite 400
Annapolis, MD 21401
Phone+1 410-897-6200

Fax+1 410-266-7636

Education & Training

University of MarylandFellowship, Hematology and Medical Oncology, 2017 - 2020
Wright-Patterson Medical CenterChief Residency, Internal Medicine, 2016 - 2017
Wright State UniversityResidency, Internal Medicine, 2013 - 2016
Eastern Virginia Medical SchoolClass of 2013

Certifications & Licensure

MD State Medical License 2017 - 2026
VA State Medical License 2014 - 2022
OH State Medical License 2013 - 2016
American Board of Internal Medicine Internal Medicine
American Board of Internal Medicine Hematology
American Board of Internal Medicine Medical Oncology

Publications & Presentations

PubMed

7 citations
Blinatumomab: a novel therapy for the treatment of non-Hodgkin’s lymphoma
Ali Bukhari, Seung Tae Lee
Expert Review of Hematology. 2019-10-16
5 citations
Low utility of the H-Score and HLH-2004 criteria to identify patients with secondary hemophagocytic lymphohistiocytosis after CAR-T cell therapy for relapsed/refractor...
Dong Won Kim, Ali Bukhari, Forat Lutfi, Facundo Zafforoni, Fikru Merechi
Leukemia & Lymphoma. 2022-06-01
80 citations
Monitoring of Circulating Tumor DNA Improves Early Relapse Detection After Axicabtagene Ciloleucel Infusion in Large B-Cell Lymphoma: Results of a Prospective Multi-In...
Matthew J. Frank, Nasheed Hossain, Ali Bukhari, Erin Dean, Jay Y. Spiegel
Journal of Clinical Oncology. 2021-06-16

Abstracts/Posters

Detectable Circulating Tumor DNA 28 Days after the CD19 CAR T-Cell Therapy, Axicabtagene Ciloleucel, Is Associated with Poor Outcomes in Patients with Diffuse Large B-...
Ali Bukhari, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Immune Effector Cell-Associated Neurotoxicity Syndrome (ICANS) after CD19-Directed Chimeric Antigen Receptor T-Cell Therapy (CAR-T) for Large B-Cell Lymphoma: Predicti...
Ali Bukhari, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019

Lectures

Increased Cortical Glycolysis Following CD19 CART Therapy: A Radiographic Surrogate for an Altered Blood-Brain Barrier
61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019